Actively Recruiting

Early Phase 1
Age: 50Years +
All Genders
NCT07053358

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-10

10

Participants Needed

1

Research Sites

234 weeks

Total Duration

On this page

Sponsors

S

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lead Sponsor

I

Innostellar Biotherapeutics Co.,Ltd

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.

CONDITIONS

Official Title

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing to sign the informed consent and attend follow-up visits
  • Age 50 years or older
  • Diagnosed with active choroidal neovascularization secondary to neovascular age-related macular degeneration
  • Best corrected visual acuity (BCVA) ETDRS letters between 5 and 63
  • Received at least 2 anti-VEGF injections within 6 months before screening and showed meaningful response
  • Fertile males with fertile female partners or fertile females agree to use effective contraception from screening until last follow-up
Not Eligible

You will not qualify if you...

  • CNV or macular edema in the study eye caused by diseases other than neovascular age-related macular degeneration
  • Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing vision improvement
  • Acute coronary syndrome, myocardial infarction, coronary artery revascularization, cerebrovascular accident (CVA), or transient ischemic attack (TIA) in the last 6 months
  • Uncontrolled hypertension with average systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg
  • Uncontrolled diabetes with HbA1c greater than 8.0% within 28 days before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China, 200080

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | DecenTrialz